DGX

DGX

USD

Quest Diagnostics Incorporated Common Stock

$178.030-1.320 (-0.736%)

실시간 가격

Healthcare
Diagnostics & Research
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$179.350

고가

$180.040

저가

$176.310

거래량

0.20M

기업 기본 정보

시가총액

19.8B

산업

Diagnostics & Research

국가

United States

거래 통계

평균 거래량

0.90M

거래소

NYQ

통화

USD

52주 범위

저가 $148.7현재가 $178.030고가 $197.55

관련 뉴스

PR Newswire

New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients,...

더 보기
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
Analyst Upgrades

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195

Barclays analyst Stephanie Davis maintains Quest Diagnostics with a Equal-Weight and raises the price target from $190 to $195.

더 보기
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195
Analyst Upgrades

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205

Truist Securities analyst David Macdonald maintains Quest Diagnostics with a Hold and raises the price target from $195 to $205.

더 보기
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205
Analyst Upgrades

Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210

Leerink Partners analyst Michael Cherny maintains Quest Diagnostics with a Outperform and raises the price target from $203 to $210.

더 보기
Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210
PR Newswire

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third...

더 보기
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Analyst Upgrades

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $190

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics with a In-Line and raises the price target from $185 to $190.